Graf Acquisition Corp. IV (GFOR)

NYSE: GFOR · IEX Real-Time Price · USD
8.30
+0.40 (5.06%)
Sep 29, 2023, 4:00 PM EDT - Market closed
Market Cap 86.10M
Revenue (ttm) n/a
Net Income (ttm) 2.92M
Shares Out 10.37M
EPS (ttm) 0.14
PE Ratio 59.29
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 113,978
Open 7.14
Previous Close 7.90
Day's Range 6.99 - 9.45
52-Week Range 5.01 - 12.88
Beta 0.03
Analysts n/a
Price Target n/a
Earnings Date n/a

About GFOR

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas. [Read more]

Industry Shell Companies
Sector Financials
IPO Date May 21, 2021
Country United States
Stock Exchange NYSE
Ticker Symbol GFOR
Full Company Profile

Financial Performance

Financial Statements

News

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023

THE WOODLANDS, Texas , Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, witho...

9 days ago - PRNewsWire

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023

THE WOODLANDS, Texas , Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, witho...

17 days ago - PRNewsWire

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023

THE WOODLANDS, Texas , Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, withou...

20 days ago - PRNewsWire

Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without conducti...

4 weeks ago - GlobeNewsWire

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovati...

5 weeks ago - GlobeNewsWire

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination

Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023

6 weeks ago - GlobeNewsWire

NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company

SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comme...

7 weeks ago - GlobeNewsWire

NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event

SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of i...

3 months ago - GlobeNewsWire

Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR) (“Graf”), announced today that it has been informed that it currently has received stockholder votes from more than 65% of...

4 months ago - Business Wire

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

SANTA ANA, Calif. and THE WOODLANDS, Texas, April 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of...

6 months ago - GlobeNewsWire

Graf Acquisition Corp. IV Withdraws Extension Proposal

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the “Company”) today announced that it is withdrawing from the ballot for its special meeting of stock...

10 months ago - Business Wire

Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021

2 years ago - Business Wire

Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

2 years ago - Business Wire

Graf Acquisition Corp. IV Announces Closing of $150 Million Initial Public Offering

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces Closing of $150 Million Initial Public Offering

2 years ago - Business Wire